| scholarly article | Q13442814 |
| P50 | author | Evelyn Ullrich | Q57151918 |
| Michel Mittelbronn | Q66360687 | ||
| Jens Schittenhelm | Q40386452 | ||
| Patrick N. Harter | Q47167318 | ||
| P2093 | author name string | Alexander Scholz | |
| Jörg Trojan | |||
| Matthias Meinhardt | |||
| Christian Braun | |||
| Roland Goldbrunner | |||
| Ulrich Herrlinger | |||
| Karl H Plate | |||
| Joachim P Steinbach | |||
| Martina Deckert | |||
| Astrid Weyerbrock | |||
| Dietmar Krex | |||
| Marco Timmer | |||
| Yvonne Reiss | |||
| Martin Glas | |||
| Oliver Bähr | |||
| Peter Baumgarten | |||
| Sebastian Cremer | |||
| Jochen T Frueh | |||
| Maiko Yamaji | |||
| Mariangela Di Tacchio | |||
| Burak H Yalcin | |||
| Kathleen Sommer | |||
| Stefanie Gurnik | |||
| P2860 | cites work | Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage | Q24295214 |
| Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels | Q24299513 | ||
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels | Q24644150 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer | Q26991997 | ||
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy | Q27690653 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing | Q28247010 | ||
| Angiopoietin signaling in the vasculature | Q28287317 | ||
| Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 | Q28570936 | ||
| Molecular mechanisms and clinical applications of angiogenesis | Q29547314 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| Epidemiology and etiology of gliomas | Q30981828 | ||
| A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors | Q31110832 | ||
| Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. | Q33416502 | ||
| Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development. | Q33626908 | ||
| Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth | Q33732486 | ||
| Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors | Q33765767 | ||
| Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer | Q34266010 | ||
| Angiopoietin-2-driven vascular remodeling in airway inflammation | Q34358380 | ||
| Antiangiogenic therapy for glioblastoma: current status and future prospects | Q34523319 | ||
| Macrophage regulation of tumor responses to anticancer therapies | Q34649588 | ||
| CSF-1R inhibition alters macrophage polarization and blocks glioma progression | Q34993852 | ||
| Angiopoietin-2 impairs revascularization after limb ischemia | Q80412365 | ||
| VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells | Q82264553 | ||
| Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner | Q84831062 | ||
| Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition | Q85428242 | ||
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial | Q88123697 | ||
| Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody | Q35604097 | ||
| Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis | Q35842980 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial | Q37240846 | ||
| Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy | Q37258307 | ||
| On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. | Q37322198 | ||
| Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system | Q37398561 | ||
| FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme | Q37629395 | ||
| Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy | Q38087230 | ||
| Tumor-associated macrophages: functional diversity, clinical significance, and open questions | Q38105286 | ||
| Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer | Q38125964 | ||
| Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation | Q38379274 | ||
| Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas | Q38942748 | ||
| VEGF regulates region-specific localization of perivascular bone marrow-derived cells in glioblastoma | Q38995812 | ||
| Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | Q39085620 | ||
| MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models | Q39397775 | ||
| Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. | Q39582827 | ||
| Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth | Q39608133 | ||
| PlGF blockade does not inhibit angiogenesis during primary tumor growth | Q39718360 | ||
| Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. | Q40100311 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis | Q41836015 | ||
| Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. | Q43041612 | ||
| A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models | Q44277060 | ||
| Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. | Q45866300 | ||
| Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. | Q45981705 | ||
| An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy | Q46538900 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation | Q46931416 | ||
| In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis | Q48100987 | ||
| Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. | Q51812262 | ||
| Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. | Q52646854 | ||
| Serum angiopoietin-2 as a clinical marker for lung cancer. | Q53570593 | ||
| Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. | Q54597476 | ||
| Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. | Q55072288 | ||
| Flt-1 signaling in macrophages promotes glioma growth in vivo. | Q55465812 | ||
| Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. | Q55476886 | ||
| P433 | issue | 1 | |
| P921 | main subject | endothelium | Q111140 |
| bevacizumab | Q413299 | ||
| P304 | page(s) | 39-57 | |
| P577 | publication date | 2015-12-14 | |
| P1433 | published in | EMBO Molecular Medicine | Q15817279 |
| P1476 | title | Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma | |
| P478 | volume | 8 |
| Q51731320 | A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models. |
| Q41574359 | A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy |
| Q88095611 | An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers |
| Q50216662 | Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy |
| Q27322343 | Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling |
| Q28070234 | Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems |
| Q37138981 | Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. |
| Q91670709 | CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q64055896 | Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma |
| Q38707904 | Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. |
| Q55012033 | Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. |
| Q55190117 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. |
| Q48093248 | Functional morphology of the blood-brain barrier in health and disease. |
| Q64912516 | Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation. |
| Q94410269 | Highlights from the Literature |
| Q55456947 | IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas. |
| Q52719932 | IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. |
| Q50055217 | Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa |
| Q92998941 | Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages |
| Q38765212 | Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. |
| Q33853991 | Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy |
| Q39433862 | Microenvironmental regulation of tumour angiogenesis |
| Q55349951 | Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. |
| Q90356200 | Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance |
| Q94599572 | N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer's disease |
| Q39022941 | New Directions in Anti-Angiogenic Therapy for Glioblastoma |
| Q38736319 | Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models |
| Q92334728 | Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy |
| Q28070053 | Pericytes, an overlooked player in vascular pathobiology |
| Q48369496 | Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. |
| Q90347558 | Resistance Mechanisms to Anti-angiogenic Therapies in Cancer |
| Q52579594 | Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. |
| Q92772956 | Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis |
| Q53082876 | Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. |
| Q92446657 | Targeting Angiogenesis in Prostate Cancer |
| Q37567174 | The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma |
| Q38675589 | The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies |
| Q90911537 | The pro-tumorigenic host response to cancer therapies |
| Q52645823 | The role of tumor microenvironment in resistance to anti-angiogenic therapy. |
| Q39321127 | Therapeutic targeting of the angiopoietin-TIE pathway |
| Q90173116 | Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma |
| Q90632936 | Tumor Endothelial Heterogeneity in Cancer Progression |
| Q91997710 | Vessel co-option in cancer |
Search more.